An Open-Label Feasibility/Pilot Study With [123I]-IBZM SPECT (DOPA-SYN)
Parkinson's Disease
About this trial
This is an interventional treatment trial for Parkinson's Disease focused on measuring Parkinson, brain imaging
Eligibility Criteria
Main inclusion criteria: The patient is aged 30 years or older. Written informed consent is obtained. Patients have a diagnosis of idiopathic Parkinson's disease. Hoehn and Yahr stages for patients are I-III. Patients have a diagnosis> 4 yrs prior to screening Patients are treated with carbidopa/levodopa with > 300 mg levodopa. Main exclusion criteria: The patient has atypical or drug-induced Parkinson's disease. The patient has dementia (MMSE 24). The patient has a clinically significant clinical laboratory values, and/or medical or psychiatric illness. The patient has any disorder that may interfere with drug absorption, distribution, metabolism, or excretion (including gastrointestinal surgery). The patient has evidence of clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematological, neoplastic, endocrine, neurological, immunodeficiency, pulmonary, or other disorder or disease. The patient has been treated with a dopamine agonist within the past 30 days. Concomitant treatment with Monoamine Oxidase (MAO)-inhibitors (except selegiline <10 mg/day) within 30 days prior to the screening visit Patient has a history of iodine allergy